Drug intelligence / Profile preview

MSV-allo (Red de Terapia Celular)

Development stage: Unknown
Lead developer: Red de Terapia Celular
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

**MSV-allo** is an investigational, donor-derived mesenchymal stromal cell therapy developed by Red de Terapia Celular. The product consists of allogeneic bone-marrow-derived mesenchymal stem/stromal cells administered by intravenous infusion. It is intended to mitigate the dysregulated inflammatory response associated with severe COVID-19 pneumonia and acute respiratory failure through broad paracrine immunomodulatory, anti-inflammatory, and tissue-repair effects rather than through a single defined molecular target. MSV-allo was evaluated in the completed randomized, double-blind, placebo-controlled Phase I/II MSV-COVID study in severe COVID-19 pneumonia and is also in Phase II development for lupus nephritis.

Other names: MSV

Beyond the preview

Go deeper on MSV-allo (Red de Terapia Celular).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSV-allo (Red de Terapia Celular).